JAK2 and myeloproliferative neoplasm: Therefore, antithrombotic prophylaxis in SVT, particularly in BCS, is an unmet clinical need and warrants prospective studies exploring the role of new direct oral anticoagulants38 and the new JAK2 inhibitors in MPN patients.